Tiagabine Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Tiagabine Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
16
Registered trials
3
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Tiagabine Hydrochloride can convert its Small molecule drug profile and GAT1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Tiagabine Hydrochloride (query alias: tiagabine) |
|---|---|
| Modality / target | Small molecule drug; GAT1; GAT1 inhibitors |
| Highest global status | Approved |
| Originator | Abbott Laboratories |
| Active developers | Teva Pharmaceuticals Australia Pty Ltd, Cephalon LLC, Beijing Jingwei Yankang Medicine Research Institute Co Ltd |
The MCP disease footprint includes Epilepsies, Partial, Epilepsy, Seizures. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTR20131851 | Phase 3 | 进行中 （招募中） | 240 | Not disclosed |
| NCT02387710 | Phase 2 | Completed | 18 | Apnea Hypopnea Index (AHI) |
| NCT01904487 | Phase 1 | Completed | 11 | To measure changes in [11C]flumazenil binding in the brain using PET scans |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Inducing Slow Wave Sleep to Treat Obstructive Sleep Apnea
Phase 2; n=18; evaluation: not stated. Reported fields: Apnea Hypopnea Index (AHI)(Median) = 40.8 events/hour (Inter-Quartile Range, 31.4 - 51.7); Apnea Hypopnea Index (AHI)(Median) = 39.1 events/hour (Inter-Quartile Range, 32.1 - 48.7); Apnea Hypopnea Index (AHI)(Median): P-Value = >0.5
Effects of Tiagabine on Slow Wave Sleep and Arousal Threshold in Patients With Obstructive Sleep Apnea.
Phase 2; n=14; evaluation: Negative. Reported fields: SWA = 2.0 LogμV2 ; SWA = 1.8 LogμV2
An Indirect Comparison of Selected Adjunctive Treatments for Refractory Partial Onset Seizures (POS): Does Evidence Matter? (P2.060)
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: 100% seizure-rate reduction = 7 fold increase in odds ; 100% seizure-rate reduction = 7 fold increase in odds ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Tiagabine Hydrochloride addresses Epilepsies, Partial, Epilepsy, Seizures. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GAT1 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-21 | Tortugas Neuroscience licensed TRTL-729 and TRTL-118 from Eisai | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Delivery of nanosized tiagabine loaded BIO-flexy films using BIO-film former from solanum lycopersicum BIO-functional agent for oro soft palatal route”. The milestone feed surfaced a patent-application signal described as “Applications of tiagabine in preparing medicines for treating dopaminergic neuron injuries”. The milestone feed surfaced a patent-application signal described as “Method for preparing tiagabine and precursor compound of tiagabine”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
